Next Article in Journal
Vitamin D3 Stimulates Proliferation Capacity, Expression of Pluripotency Markers, and Osteogenesis of Human Bone Marrow Mesenchymal Stromal/Stem Cells, Partly through SIRT1 Signaling
Next Article in Special Issue
Neurons with Cat’s Eyes: A Synthetic Strain of α-Synuclein Fibrils Seeding Neuronal Intranuclear Inclusions
Previous Article in Journal
Cytoplasmic and Nuclear Functions of cIAP1
Previous Article in Special Issue
How Lazy Reading and Semantic Sloppiness May Harm Progress in Synucleinopathy Research
Hypothesis

Production of Recombinant Alpha-Synuclein: Still No Standardized Protocol in Sight

1
Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, Waldweg 33, 37073 Göttingen, Germany
2
Max Planck Institute for Experimental Medicine, 37075 Göttingen, Germany
3
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE1 7RU, UK
4
Scientific Employee with an Honorary Contract at German Center for Neurodegenerative Diseases (DZNE), 37075 Göttingen, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: François Ichas
Biomolecules 2022, 12(2), 324; https://doi.org/10.3390/biom12020324
Received: 22 December 2021 / Revised: 15 February 2022 / Accepted: 16 February 2022 / Published: 18 February 2022
Synucleinopathies are a group of neurodegenerative diseases, characterized by the abnormal accumulation of the protein alpha-synuclein (aSyn). aSyn is an intrinsically disordered protein that can adopt different aggregation states, some of which may be associated with disease. Therefore, understanding the transitions between such aggregation states may be essential for deciphering the molecular underpinnings underlying synucleinopathies. Recombinant aSyn is routinely produced and purified from E. coli in many laboratories, and in vitro preparations of aSyn aggregated species became central for modeling neurodegeneration in cell and animal models. Thus, reproducibility and reliability of such studies largely depends on the purity and homogeneity of aSyn preparations across batches and between laboratories. A variety of different methods are in use to produce and purify aSyn, which we review in this commentary. We also show how extraction buffer composition can affect aSyn aggregation, emphasizing the importance of standardizing protocols to ensure reproducibility between different laboratories and studies, which are essential for advancing the field. View Full-Text
Keywords: alpha-synuclein; Parkinson’s disease; aggregation; synucleinopathies; amyloid alpha-synuclein; Parkinson’s disease; aggregation; synucleinopathies; amyloid
Show Figures

Figure 1

MDPI and ACS Style

Al-Azzani, M.; König, A.; Outeiro, T.F. Production of Recombinant Alpha-Synuclein: Still No Standardized Protocol in Sight. Biomolecules 2022, 12, 324. https://doi.org/10.3390/biom12020324

AMA Style

Al-Azzani M, König A, Outeiro TF. Production of Recombinant Alpha-Synuclein: Still No Standardized Protocol in Sight. Biomolecules. 2022; 12(2):324. https://doi.org/10.3390/biom12020324

Chicago/Turabian Style

Al-Azzani, Mohammed, Annekatrin König, and Tiago F. Outeiro. 2022. "Production of Recombinant Alpha-Synuclein: Still No Standardized Protocol in Sight" Biomolecules 12, no. 2: 324. https://doi.org/10.3390/biom12020324

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop